Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials With Ely Lilly
By Adriano Marchese
Foghorn Therapeutics and Eli Lilly will abandon joint development of their lead oncology candidate and cut roughly 40% of Foghorn's workforce following disappointing phase 1 trial results.
Foghorn shares in Thursday's premarket trading were down 44% to $2.00.
The biotechnology company on Thursday said they have decided to stop advancing FHD-909 into the clinical development expansion phase, and end their SMARCA2 partnership after data showed the drug failed to deliver sufficient efficacy in targeting lung cancer.
"Unfortunately, the biology of the SMARCA2/4 synthetic lethality relationship has not translated into the level of efficacy required to further advance the program," said Foghorn Chief Executive Adrian Gottschalk.
Foghorn's board approved a strategic reprioritization on Sept. 30 that will eliminate about 40% of its staff-leaving the biotech with roughly 65 full-time employees.
The moves are expected to extend the company's cash runway to fund its priority programs into the second half of 2029.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 01, 2026 07:55 ET (11:55 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States